Elevance Health, Inc. (ELV)

Over the past six months, Elevance Health's stock has declined by 22.57%. Key events include the Q1 2025 earnings release with an EPS of $9.61, and the Q2 2025 earnings release with an EPS of $8.84, missing estimates. Management lowered its full-year adjusted EPS guidance due to elevated medical costs and slower Medicaid rate alignments. A quarterly dividend of $1.71 was paid on September 25, 2025. The U.S. Commerce Department launched a national security investigation into medical equipment imports, causing shares to drop. Several analysts adjusted their price targets and ratings for ELV during this period.

Information directly detailing strong demand seasonality for Elevance Health's products and services is not explicitly provided. Health insurance and healthcare services can exhibit seasonal patterns, such as enrollment periods or fluctuations in healthcare utilization. The company's revenue growth has slowed, and customer numbers saw a slight decrease in Q2 2025, partly due to reductions in Medicaid membership and lower effectuation rates in the ACA business.

Elevance Health, Inc. is a health benefits company in the United States, focused on improving health outcomes and overall well-being. It offers health plans and services to various groups, including individuals, employer groups, and Medicare/Medicaid members. The company's services include medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Elevance Health operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It is a major player in pharmacy services and operates under brands like Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon. Elevance Health is the largest for-profit managed healthcare company within the Blue Cross Blue Shield Association, serving as the licensee in 14 states.

Elevance Health primarily operates within the United States as a Blue Cross Blue Shield Association licensee in 14 states. Its reach extends through government-sponsored programs like Medicaid and Medicare Advantage plans via acquisitions like Amerigroup and MMM. The company intends to acquire Blue Cross and Blue Shield of Louisiana, potentially expanding its presence to 15 states. Its Carelon Global Solutions subsidiary operates in India, Israel, Puerto Rico, the Philippines, the United States, and Ireland.

Elevance Health's brand reputation has been influenced by its financial performance and operations in the healthcare landscape. The company has faced historical controversies, including data breaches and issues related to denial of benefits. Its resilience in the health insurance market, driven by fee-based Commercial plans and preventive care initiatives, has been highlighted as a positive aspect. Its focus on administrative services only plans helps shield it from rising medical costs, contributing to a stable perception among clients.

Elevance Health is predominantly owned by institutional shareholders, holding approximately 90.64% of the stock. Vanguard Group Inc is the largest individual shareholder, owning 10.15% of the company. Insiders own about 2.66% of the stock, while retail investors hold approximately 6.70%.